Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ascrinvacumab
- Development stage
- Phase 2
- Lead developer
- Kintor Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intravitreal
01
Overview
Ascrinvacumab is a fully human IgG2 monoclonal antibody that targets activin receptor-like kinase 1 (ALK-1, also known as ACVRL1), a receptor involved in the TGF-beta signaling pathway. By binding to and neutralizing ALK-1, ascrinvacumab disrupts tumor endothelial cell function and inhibits angiogenesis, which can lead to reduced tumor growth and proliferation. It has been investigated primarily for the treatment of various cancers, including hepatocellular carcinoma, advanced solid tumors, malignant pleural mesothelioma, colorectal cancer, urogenital cancer, and age-related macular degeneration. The drug was originally developed by Pfizer and later by Suzhou Kintor Pharmaceuticals in collaboration with Duke University Medical Center and Fondazione IRCCS Istituto Nazionale dei Tumori[1][2][3][4][5].
- Other names
- ascrinvacumab
02
Targets
ACVRL1 (Activin receptor-like kinase 1)
Beyond the preview
Go deeper on ascrinvacumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ascrinvacumab.